

**Report Pursuant to National Instrument 62-103
and Section 5.2 of Multilateral Instrument 62-104**

1. Security and Reporting Issuer

This report is made pursuant to the provisions of the securities legislation referred to above in connection with an acquisition of securities of Nirvana Life Sciences Inc. (formerly Endocan Solutions Inc.) (the “Company” or “Nirvana”), 2110, 650 West Georgia Street, Vancouver, BC, V6B 4N8. The securities of Nirvana were acquired through the completion of the previously announced acquisition (the “Acquisition”) of 1253766 B.C. Ltd. (formerly Nirvana Life Sciences Inc) (the “Private Company”), in which Nirvana issued 25,905,095 common shares of the Company as consideration for 25,905,095 common shares of the Private Company.

2. Identity of Acquiror

Sheldon Inwentash
126 Old Forest Hill Road
Toronto, ON M5P 2R9

The Company announced the completion of the Acquisition on March 14, 2022. The Acquisition was considered to be a reverse takeover transaction and the common shares of the Company began publicly trading on the Canadian Securities Exchange on March 18, 2022. The Acquisition involved the following joint actor of Sheldon Inwentash (“Inwentash”):

- ThreeD Capital Inc. (the “Joint Actor”), 130 Spadina Avenue, Suite 401, Toronto, ON, M5V 2L4

3. Interest in Securities of the Reporting Issuer

Inwentash and the Joint Actor originally acquired securities of the Private Company in February 2021 as part of a private placement transaction. Pursuant to the Acquisition, Inwentash and the Joint Actor received an aggregate 4,500,000 common shares of Nirvana in exchange for an aggregate 4,500,000 common shares of the Private Company. As a result of the Acquisition, the percentage ownership of Inwentash and the Joint Actor on a partially dilutive basis exceeded 10% of the issued and outstanding shares of the Company.

Immediately prior to the Acquisition, Inwentash and the Joint Actor owned and controlled an aggregate of 4,500,000 common shares of the Private Company, representing approximately 17.3% of all issued and outstanding common shares of the Private Company on a non-dilutive and partially dilutive basis. Of this total, Inwentash held an aggregate 1,500,000 common shares of the Private Company, representing approximately 5.8% of the issued and outstanding common shares of the Private Company on a non-dilutive and partially dilutive basis. The Joint actor held an aggregate of 3,000,000 common shares of the Private Company, representing approximately 11.5% of the issued and outstanding common shares of the Private Company on a non-dilutive and partially dilutive basis.

Immediately following the Acquisition, Inwentash and the Joint Actor own and control an aggregate of 4,500,000 common shares of Nirvana, representing approximately 13.6% of all issued and outstanding common shares of the Company on a non-dilutive and partially dilutive basis. Of this total, Inwentash holds an aggregate of 1,500,000 common shares of the Company, representing approximately 4.5% of the issued and outstanding common shares of the Company on a non-dilutive and partially dilutive basis. The Joint Actor holds an aggregate of 3,000,000 common shares of the Company, representing approximately 9.1% of the issued and outstanding common shares of the Company on a non-dilutive and partially dilutive basis.

4. Consideration Paid

Inwentash and the Joint Actor received an aggregate 4,500,000 common shares of Nirvana in exchange for an aggregate 4,500,000 common shares of the Private Company.

The common shares of the Private Company were originally purchased through a private placement at a price of \$0.15 per Private Company common share for total proceeds paid of \$675,000.

5. Purpose of the Transaction

The holdings of securities of the Company by Inwentash and the Joint Actor are managed for investment purposes. Inwentash and the Joint Actor may from time to time acquire additional securities of the Company, dispose of some or all of the existing or additional securities it holds or will hold, or may continue to hold its current position.

6. Agreements, Arrangements, Commitments or Understandings with respect to Securities of the Company

Not Applicable.

7. Change in Material Fact.

Not Applicable.

8. Exemption.

Section 2.3 of National Instrument 45-106 on the basis that each of Inwentash and the Joint Actor is a “accredited investor” as defined therein.

9. Certification

The undersigned certifies that the information herein is true and complete in every respect.

DATED this 22nd day of March 2022

“Sheldon Inwentash”

Sheldon Inwentash